These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 3044442)

  • 1. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
    Lokhorst HM; Boom SE; Terpstra W; Roholl P; Gerdes J; Bast BJ
    Br J Haematol; 1988 Aug; 69(4):477-81. PubMed ID: 3044442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
    Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
    Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of plasma cell infiltrates in the bone marrow. A clinicopathological study on 80 patients including immunohistochemistry and morphometry.
    Thiele J; Arenz B; Klein H; Vierbuchen M; Zankovich R; Fischer R
    Virchows Arch A Pathol Anat Histopathol; 1988; 412(6):553-62. PubMed ID: 3129867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
    Dehou MF; Schots R; Lacor P; Arras N; Verhavert P; Klöppel G; van Camp B
    Am J Clin Pathol; 1990 Sep; 94(3):287-91. PubMed ID: 1697732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
    Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
    Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
    Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell morphology in multiple myeloma and related disorders.
    Ribourtout B; Zandecki M
    Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the immunoperoxidase technic to bone marrow trephine biopsies in the classification of patients with monoclonal gammopathies.
    Peterson LC; Brown BA; Crosson JT; Mladenovic J
    Am J Clin Pathol; 1986 Jun; 85(6):688-93. PubMed ID: 3085474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
    Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
    Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
    Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interpretation of minimal medullary plasmacytoses in monoclonal dysglobulinemias. Importance of the study of osteomedullary biopsies of semi-thin sections and immunologic marking].
    Canioni D; Kermarec J
    Ann Pathol; 1982; 2(4):279-92. PubMed ID: 6760876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.
    Lokhorst HM; Boom SE; Bast BJ; Peters PJ; Tedder TF; Gerdes J; Petersen E; Ballieux RE
    J Clin Invest; 1987 May; 79(5):1401-11. PubMed ID: 3553239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.
    Greipp PR; Kyle RA
    Blood; 1983 Jul; 62(1):166-71. PubMed ID: 6407546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies.
    Falini B; Canino S; Sacchi S; Ciani C; Martelli MF; Gerdes J; Stein H; Pileri S; Gobbi M; Fagioli M
    Br J Haematol; 1988 Jul; 69(3):311-20. PubMed ID: 3165668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD52 on plasma cells in plasma cell proliferative disorders.
    Kumar S; Kimlinger TK; Lust JA; Donovan K; Witzig TE
    Blood; 2003 Aug; 102(3):1075-7. PubMed ID: 12714489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.